Docket Room.
S 1414·Federal·senate

Expedited Access to Biosimilars Act

Floor Vote ScheduledFiled Apr 10, 2025
Sponsor: Sen. Paul, Rand [R-KY] (R)
Latest Action

Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.

Jul 27, 2026

Email me when S 1414 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track S 1414. By continuing you agree to the Terms and Privacy Policy.

Legislative status

  1. Introduced
  2. In Committee
  3. Reported by Committee
  4. Floor Vote Scheduled
  5. Passed One Chamber
  6. Passed Both Chambers
  7. Sent to Executive
  8. Signed into Law

Summary

The Expedited Access to Biosimilars Act would create a faster pathway for biosimilar drugs to reach the market, potentially lowering costs for patients. It targets pharmaceutical manufacturers, healthcare providers, and consumers who rely on biologic therapies, and it has been favorably reported by the Senate Health, Education, Labor, and Pensions Committee.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about S 1414

3 free questions a day, no account

Hearings

History

  1. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Introduced in Senate

Sponsors

  • Sen. Paul, Rand [R-KY] (R) · sponsor
  • Sen. Lee, Mike [R-UT] (R)

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when S 1414 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track S 1414 free

Or ask your AI assistant about S 1414 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice